Very Disappointed. During Saturday presentation everybody in thus company seemed to be lost. They are still looking for people to their product .
Then I read a old presentation and it is the same presentation claiming the “Christmas miracle “ I am done . Lost some pennies GLTA

Piloto
Posts (1263)
Do not sell cheap
Somebody has been buying stock to bring it down . Be careful . Tomorrow will be tough
It looks like AMPE is staying as the only possibility as therapeutic to reduce COVID’ death rate. Bad news for Lily . Read this
Baricitinib is a repurposed arthritis treatment that, like a steroid, dampens inflammation, which, in severe cases of COVID-19, can spiral out of control and destroy healthy tissues. The drug acts like a molecular muffler, preventing the cells from responding to alarm signals that could make the body’s immune response spiral out of control.
The NIH trial was designed to test whether baricitinib could boost the benefits of remdesivir, now the standard of care for COVID-19 patients. Remdesivir by itself speeds recovery by several days. The researchers found that the addition of baricitinib clipped an additional day off a patient’s recovery time and kept a few extra people off ventilators. But these and other results largely failed to impress experts, many of whom said the drug would need to have far bigger benefits to outweigh its price tag and potential harms.
In a statement on Wednesday, Merck said it sold its equity stake in Moderna in the first half of the fourth quarter, adding that it achieved a "substantial gain" on its holdings.
Shares of Moderna traded down as much as 9% in early morning trades, but have since recovered as of Wednesday afternoon.
Merck initially invested $50 million in Moderna before it was public in 2015, and subsequently invested $125 million in the company in 2018. Moderna went public in late 2018.
In a statement on Wednesday, Merck said it sold its equity stake in Moderna in the first half of the fourth quarter, adding that it achieved a "substantial gain" on its holdings.
Shares of Moderna traded down as much as 9% in early morning trades, but have since recovered as of Wednesday afternoon.
Merck initially invested $50 million in Moderna before it was public in 2015, and subsequently invested $125 million in the company in 2018. Moderna went public in late 2018.
First big investor jumping from the boat .
“Merck sells its investment stake in Moderna after recording a 'substantial' gain”
Is this is going to grow more why to jumbo now ... uhh
Nice assessment Kevin
Typical of RS. Be careful .
Vanguard and Blackrock increased they shares by 50% .
